EZH2: An Accomplice of Gastric Cancer
Cancers · 09.01.2023 · 15 (2) · 425
DOI: 10.3390/cancers15020425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.01.2023. Verfasst von Wuhan Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital of Lanzhou University, Lanzhou 730030, China. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gansu Province Youth Science and Technology Fund program, Chinese foundation for hepatitis prevention and control--TianQing liver disease research fund subject, Science and technology projects in Cheng-guan District of Lanzhou City.
Abstract (Originalsprache)
Gastric cancer is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Understanding the factors influencing the therapeutic effects in gastric cancer patients and the molecular mechanism behind gastric cancer is still facing challenges. In addition to genetic alterations and environmental factors, it has been demonstrated that epigenetic mechanisms can also induce the occurrence and progression of gastric cancer. Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressor complex 2 (PRC2), which trimethylates histone 3 at Lys-27 and regulates the expression of downstream target genes through epigenetic mechanisms. It has been found that EZH2 is overexpressed in the stomach, which promotes the progression of gastric cancer through multiple pathways. In addition, targeted inhibition of EZH2 expression can effectively delay the progression of gastric cancer and improve its resistance to chemotherapeutic agents. Given the many effects of EZH2 in gastric cancer, there are no studies to comprehensively describe this mechanism. Therefore, in this review, we first introduce EZH2 and clarify the mechanisms of abnormal expression of EZH2 in cancer. Secondly, we summarize the role of EZH2 in gastric cancer, which includes the association of the EZH2 gene with genetic susceptibility to GC, the correlation of the EZH2 gene with gastric carcinogenesis and invasive metastasis, the resistance to chemotherapeutic drugs of gastric cancer mediated by EZH2 and the high expression of EZH2 leading to poor prognosis of gastric cancer patients. Finally, we also clarify some of the current statuses of drug development regarding targeted inhibition of EZH2/PRC2 activity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Hospital of Lanzhou University, Lanzhou 730030, China.
- The Second General Surgery Department, The Second Hospital of Lanzhou University, Lanzhou 730030, China.
- The Neurology Department, The Second Hospital of Lanzhou University, Lanzhou 730030, China.
- The Cardiology Department, The Second Hospital of Lanzhou University, Lanzhou 730030, China.
Förderung
- Gansu Province Youth Science and Technology Fund program
- Chinese foundation for hepatitis prevention and control--TianQing liver disease research fund subject
- Science and technology projects in Cheng-guan District of Lanzhou City
- Lanzhou city science and technology development guidance plan
- Gansu Provincial Administration of Traditional Chinese Medicine Scientific Research Project
- Chinese Foundation for Hepatitis Prevention and Control—TianQing liver disease research fund subject
Zitieren
APA
Yu, W., Liu, N., Song, X., Chen, L., Wang, M., Xiao, G., Li, T., Wang, Z., & Zhang, Y. (2023). EZH2: An Accomplice of Gastric Cancer. Cancers, 15(2), 425. https://doi.org/10.3390/cancers15020425
Vancouver
Yu W, Liu N, Song X, Chen L, Wang M, Xiao G, et al. EZH2: An Accomplice of Gastric Cancer. Cancers. 2023;15(2):425. doi:10.3390/cancers15020425
BibTeX
@article{Yu2023,
author = {Yu, Wuhan and Liu, Ning and Song, Xiaogang and Chen, Lang and Wang, Mancai and Xiao, Guohui and Li, Tengfei and Wang, Zheyuan and Zhang, Youcheng},
title = {EZH2: An Accomplice of Gastric Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {2},
pages = {425},
doi = {10.3390/cancers15020425}
}
EUVIMED